Federal court finds two Latisse patents invalid

Article

The U.S. Court of Appeals for the Federal Circuit in Washington, D.C. recently found a pair of patents for Allergan’s Latisse (bimatoprost) invalid and threw out an order preventing Novartis’ Sandoz unit, Actavis, and generic drug company Apotex Inc. from selling their versions of the eyelash growth drug.

Washington, D.C.-The U.S. Court of Appeals for the Federal Circuit in Washington, D.C. recently found a pair of patents for Allergan’s Latisse (bimatoprost) invalid and threw out an order preventing Novartis’ Sandoz unit, Actavis, and generic drug company Apotex Inc. from selling their versions of the eyelash growth drug.

Latisse is a variation of the glaucoma drug Lumigan (bimatoprost). The patents, which are owned by Allergan and Duke University and were set to expire in 2022 and 2024, covered ways to apply the chemical compound to promote eyelash growth. Allergan recently estimated that Latisse sales would reach $100 million to $110 million in 2014. 

A patent on forms of Lumigan is set to expire in August, but Allergan won a lawsuit earlier this year involving a formulation for the 0.01 percent solution that will keep that specific version of the drug off the market through 2027. But Sandoz and other generic drug manufacturers are appealing that decision. 

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Presenters from the Collaborative Care Symposium 2025 give their key takeaways from their presentations.
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
© 2025 MJH Life Sciences

All rights reserved.